Bladder cancer
UPDATED --- First-line therapy of synchronous and metachronous metastatic UCa
Lernziel: Recognise factors impacting the choice of first-line therapy for synchronous or metachronous metastatic urothelial carcinoma (UCa), e.g. eligibility to (combination) therapies defined by ECOG PS, GFR, comorbidities, FGFR status, and receipt of prior systemic therapy in the M0 setting.
Fachgebiet: Medical oncology, urology, clinical oncology, (radiation oncology)
Zielpublikum: Specialists (CME: basic, intermediate), Residents (senior)
Letzte Aktualisierung: October 2024
Hintergrund:
Regulatory approval status of drugs limited to the metastatic UCa setting (status 14 October 2024)
ChT: chemotherapy; CPS: combined positive score; PD-(L)1: programmed death-(ligand) 1
In all cases presented in this topic, it is assumed that the relevant antibodies/tests are used for PD-L1 and FGFR testing.
This educational platform includes case challenges with treatment options that may not be indicated for this use in your country. Please refer to your local prescribing information.